Business
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
-$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3
About this update from Bridgebio Pharma, Inc.
- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025 , 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - Attruby continues to differentiate clinically by proving its unique profile in new subpopulations and holistic analyses: - JACC publication demonstrated the effect of Attruby on cumulative cardiovascular outcomes within the first month of treatment - Positive topline interim analysis results from FORTIFY, the registrational Phase 3 study of BBP-418, a small molecule in development for LGMD2I/R9 - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p
View stock analysis, news, and events for Bridgebio Pharma, Inc.